Evidence map›Paper›PMID 35793959›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Diffuse Large B-cell Lymphoma with Adrenal Involvement Presenting as Other Iatrogenic Immunodeficiency-associated Lymphoproliferative Disorders: Sustained Remission with Methotrexate Termination Alone in Two Cases.

Hajime Yasuda, Jun Ando, Sayako Yoshida, Yasunori Ota, Norio Komatsu, Miki Ando

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. CD5Discover oncology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hajime YasudaDepartment of Hematology, Juntendo University School of Medicine, Japan.
Jun AndoDepartment of Hematology, Juntendo University School of Medicine, Japan.
Sayako YoshidaDepartment of Hematology, Juntendo University School of Medicine, Japan.
Yasunori OtaDepartment of Pathology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Japan.
Norio KomatsuDepartment of Hematology, Juntendo University School of Medicine, Japan.
Miki AndoDepartment of Hematology, Juntendo University School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methotrexate-associated lymphoproliferative disorders (MTX-LPDs) with diffuse large B-cell lymphoma (DLBCL) pathology present with high rates of spontaneous regression after methotrexate (MTX) termination, especially in Epstein-Barr virus-encoded RNA (EBER)-positive cases. DLBCL with adrenal involvement is known for an extremely dismal prognosis. However, the prognosis of adrenal DLBCL in the context of MTX-LPD is unknown. We herein report two EBER-positive adrenal DLBCL MTX-LPD patients who achieved long-term remissions of 22 and 40 months with MTX termination alone. Both patients are doing well with no relapse at the time of reporting. Unlike adrenal DLBCL in general, adrenal involvement may not be a poor prognostic factor when restricted to DLBCL MTX-LPDs.

Indexed as

Arthritis, RheumatoidEpstein-Barr Virus InfectionsImmunologic Deficiency SyndromesLymphoma, Large B-Cell, DiffuseLymphoproliferative DisordersHerpesvirus 4, HumanHumansIatrogenic DiseaseMethotrexateNeoplasm Recurrence, LocalMethotrexateEBERMTX-LPDsOIIA-LPDsPALprimary adrenal lymphoma

Identifiers

PMID35793959
PMCPMC10017257

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.